{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:27:58Z","timestamp":1794644878562,"version":"4.9.1"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T00:00:00Z","timestamp":1244764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>Recent data suggest that tryptase, a mast cell enzyme, is expressed in neoplastic cells in myeloid leukaemias. In several of these patients, increased serum tryptase levels are detectable.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold>We have determined serum tryptase levels in 914 patients with haematological malignancies, including myeloproliferative disorders (<jats:italic>n<\/jats:italic>\u2003=\u2003156), myelodysplastic syndromes (MDS,<jats:italic>n<\/jats:italic>\u2003=\u2003241), acute myeloid leukaemia (AML,<jats:italic>n<\/jats:italic>\u2003=\u2003317), systemic mastocytosis (SM,<jats:italic>n<\/jats:italic>\u2003=\u200381), non\u2010Hodgkin\u2032s lymphoma (<jats:italic>n<\/jats:italic>\u2003=\u200359) and acute lymphoblastic leukaemia (<jats:italic>n<\/jats:italic>\u2003=\u200326). Moreover, tryptase was measured in 136 patients with non\u2010neoplastic haematological disorders, 102 with non\u2010haematological disorders and 164 healthy subjects.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>In healthy subjects, the median serum tryptase was 5\u00b72\u2003ng\u2003mL<jats:sup>\u22121<\/jats:sup>. Elevated serum tryptase levels were found to cluster in myeloid neoplasm, whereas almost all patients with lymphoid neoplasms exhibited normal tryptase. Among myeloid neoplasms, elevated tryptase levels (&gt;\u200315\u2003ng\u2003mL<jats:sup>\u22121<\/jats:sup>) were recorded in &gt;\u200390% of patients with SM, 38% with AML, 34% with CML and 25% with MDS. The highest tryptase levels, often &gt;\u20031000\u2003ng\u2003mL<jats:sup>\u22121<\/jats:sup>, were found in advanced SM and core\u2010binding\u2010factor leukaemias. In most patients with non\u2010neoplastic haematological disorders and non\u2010haematological disorders analysed in our study, tryptase levels were normal, the exception being a few patients with end\u2010stage kidney disease and helminth infections, in whom a slightly elevated tryptase was found.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold>In summary, tryptase is a new diagnostic marker of myeloid neoplasms and a useful test in clinical haematology.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02184.x","type":"journal-article","created":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T16:07:41Z","timestamp":1244822861000},"page":"914-923","source":"Crossref","is-referenced-by-count":90,"title":["Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology"],"prefix":"10.1111","volume":"39","author":[{"given":"W. R.","family":"Sperr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"El\u2010Samahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Girschikofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Endler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Agis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sillaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2335924100"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.020"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200402053"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10869"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1519"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313020310001648404"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2200"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000059404"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290021470"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0732"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)68496-6"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121454"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706253162603"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118337"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00020-0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_7_18_2","first-page":"293","volume-title":"World Health Organization (WHO) Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues","author":"Valent P","year":"2001"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2580"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0006"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2274"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"206B","DOI":"10.1182\/blood.V106.11.4510.4510","article-title":"Serum tryptase levels in acute leukemia at diagnosis: correlation with CBF AML","volume":"106","author":"Cairoli R","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"668A","DOI":"10.1182\/blood.V108.11.2358.2358","article-title":"Serum tryptase levels in AML at diagnosis: a multicenter retrospective study","volume":"108","author":"Cairoli R","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01533368"},{"key":"e_1_2_7_25_2","first-page":"79","article-title":"Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis","volume":"110","author":"Wimazal F","year":"1998","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.008"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200164"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1064"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.11.009"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.03.015"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.11.010"},{"key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ajcp\/75.1.34","article-title":"Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders","volume":"75","author":"Prokocimer M","year":"1981","journal-title":"Am J Pathol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-028456"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1309\/M9FQMQGF66167N2X"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02184.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02184.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:25:16Z","timestamp":1739157916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02184.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,15]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02184.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02184.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,15]]}}}